HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.

Abstract
Glucocorticoids (GCs) are the most commonly used antiinflammatory and immunosuppressive drugs. Their outstanding therapeutic effects, however, are often accompanied by severe and sometimes irreversible side effects. For this reason, one goal of research in the GC field is the development of new drugs, which show a reduced side-effect profile while maintaining the antiinflammatory and immunosuppressive properties of classical GCs. GCs affect gene expression by both transactivation and transrepression mechanisms. The antiinflammatory effects are mediated to a major extent via transrepression, while many side effects are due to transactivation. Our aim has been to identify ligands of the GC receptor (GR), which preferentially induce transrepression with little or no transactivating activity. Here we describe a nonsteroidal selective GR-agonist, ZK 216348, which shows a significant dissociation between transrepression and transactivation both in vitro and in vivo. In a murine model of skin inflammation, ZK 216348 showed antiinflammatory activity comparable to prednisolone for both systemic and topical application. A markedly superior side-effect profile was found with regard to increases in blood glucose, spleen involution, and, to a lesser extent, skin atrophy; however, adrenocorticotropic hormone suppression was similar for both compounds. Based on these findings, ZK 216348 should have a lower risk, e.g., for induction of diabetes mellitus. The selective GR agonists therefore represent a promising previously undescribed class of drug candidates with an improved therapeutic index compared to classical GCs. Moreover, they are useful tool compounds for further investigating the mechanisms of GR-mediated effects.
AuthorsHeike Schäcke, Arndt Schottelius, Wolf-Dietrich Döcke, Peter Strehlke, Stefan Jaroch, Norbert Schmees, Hartmut Rehwinkel, Hartwig Hennekes, Khusru Asadullah
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 101 Issue 1 Pg. 227-32 (Jan 06 2004) ISSN: 0027-8424 [Print] United States
PMID14694204 (Publication Type: Journal Article)
Chemical References
  • Anti-Inflammatory Agents
  • Benzofurans
  • Benzoxazines
  • Glucocorticoids
  • Interleukin-8
  • Ligands
  • Protein Subunits
  • Receptors, Glucocorticoid
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • ZK 216348
  • Interleukin-12
  • Prednisolone
  • Tyrosine Transaminase
Topics
  • Animals
  • Anti-Inflammatory Agents (administration & dosage, pharmacology, toxicity)
  • Benzofurans (administration & dosage, pharmacology, toxicity)
  • Benzoxazines
  • Enzyme Induction (drug effects)
  • Glucocorticoids (administration & dosage, pharmacology, toxicity)
  • Humans
  • In Vitro Techniques
  • Interleukin-12 (biosynthesis)
  • Interleukin-8 (biosynthesis)
  • Leukocytes, Mononuclear (drug effects, immunology, metabolism)
  • Ligands
  • Mice
  • Prednisolone (administration & dosage, pharmacology, toxicity)
  • Protein Subunits (biosynthesis)
  • Rats
  • Rats, Wistar
  • Receptors, Glucocorticoid (agonists, genetics, metabolism)
  • Recombinant Proteins (agonists, genetics, metabolism)
  • Skin (drug effects)
  • Transcriptional Activation (drug effects)
  • Tumor Necrosis Factor-alpha (biosynthesis)
  • Tyrosine Transaminase (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: